Clinical studies on the EEG-activating effects of a new central stimulant, sodium-beta, beta-pentamethylene-gamma-hydroxybutyrate.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001534:Bemegride; D002490:Central Nervous System / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000009:adverse effects; D002648:Child; D002986:Clinical Trials as Topic; D004569:Electroencephalography; D004827:Epilepsy / Q000175:diagnosis*; D005260:Female; D006801:Humans; D006885:Hydroxybutyrates; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010433:Pentylenetetrazole
D000697:Central Nervous System Stimulants; D006885:Hydroxybutyrates; D001534:Bemegride; D010433:Pentylenetetrazole